Roche and Novartis are working hard on next-generation drugs for wet age-related macular degeneration, and they’re hoping to steal significant market share away from entrenched drugs like Regeneron’s Eylea. But analysts aren’t convinced the new candidates can do the job.
read moreEstradiol and progesterone are two commonly used female hormone therapies, but until now they have only been approved by the FDA as combo therapy identical to the hormones produced naturally in a woman’s body. More: TherapeuticsMD gears up to launch
read moreMerck’s Gardasil franchise generated $1 billion in the third quarter, prompting an analyst to wonder just how much the shot might be able to generate in the long run. More: 'Unprecedented' demand for Merck's Gardasil drives monster Q3 Source: fierce
read moreAmid reports that it is aiming to sell Shire’s Xiidra and Natpara to pay down deal-related debt, Takeda has proposed jettisoning another piece of Shire’s portfolio. The phase 3 inflammatory bowel disease candidate SHP647, which could overlap with Takeda’s own
read moreAspen Pharmacare has seen some financial weakness lately, but that hasn’t stopped it from pledging to make its largest manufacturing investment ever. The South African drugmaker says it will invest nearly $235 million in a facility to manufacture sterile anesthetics. More:
read moreNovartis and Pfizer have announced an agreement that aims to advance the treatment of non-alcoholic steatohepatitis (NASH), a form of liver disease. More: Novartis and Pfizer link to develop NASH combo therapy Source: News
read more© 1994 - 2025 B.M. Pharmaceuticals